COLLECTION AND ANALYSIS OF DRUG SAFETY DATA IN PREGNANCY

Main Article Content

Myla Moretti

Keywords

DRUG SAFETY, PREGNANCY

Abstract

Much of what I will touch on will be taken from the perspective of Motherisk, where we as service providers speak to patients and practitioners on a day to day basis.

Abstract 65 | PDF Downloads 45

References

1. Moretti M, Koren G. Motherisk: The Toronto Model for Counseling in Reproductive Toxicology. 2004: 767-789.
2. Bonati M, Bortolus R, Marchetti F, Romero M, Tognoni G. Drug use in pregnancy: an overview of epidemiological (drug utilization) studies. Eur J Clin Pharmacol 1990;38:325-328.
3. Reiff-Eldridge R, Heffner CR, Ephross SA, Tennis PS, White AD, Andrews EB. Monitoring pregnancy outcomes after prenatal drug exposure
through prospective pregnancy registries: a pharmaceutical company commitment. Am J Obstet Gynecol 2000;182:159-163.
4. US Food and Drug Administration. Guidance for industry establishing pregnancy exposure registries. Rockville (MD): US Department of
Health and Human Services; 2002.
5. Rosa F. Databases in the assessment of the effects of drugs during pregnancy. J Allergy Clin Immunol 1999;103:S360-S361.
6. Axelsson O. The Swedish medical birth register. Acta Obstet Gynecol Scand 2003;82:491-492.
7. Moretti ME, Caprara D, Coutinho CJ et al. Fetal safety of loratadine use in the first trimester of pregnancy: a multicenter study. J Allergy Clin
Immunol 2003;111:479-483.